ALAron H. Lichtman

Aron H. Lichtman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aron H. Lichtman has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Δ9-Tetrahydrocannbinol Accounts for the Antinociceptive, Hypothermic, and Cataleptic Effects of Marijuana in Mice

    by S. A. Varvel, D. T. Bridgen, Q. Tao, B. F. Thomas, B. R. Martin, A. H. Lichtman

    Although it is widely accepted that Δ9-tetrahydrocannabinol (Δ9-THC) is the primary psychoactive constituent of marijuana, questions persist as to whether other components contribute to marijuana's pharmacological activity. The present experiments assessed the cannabinoid activity of marijuana smoke exposure in mice and tested the hypothesis that Δ9-THC mediates these effects through a CB1 receptor mechanism of action. First, the effects of Δ9-THC on analgesia, hypothermia, and catalepsy were compared with those of a marijuana extract with equated Δ9-THC content after either i.v. administration or inhalation exposure. Second, mice were exposed to smoke of an ethanol-extracted placebo plant material or low-grade marijuana (with minimal Δ9-THC but similar levels of other cannabinoids) that were impregnated with varying quantities of Δ9-THC. To assess doses, Δ9-THC levels in the blood and brains of drug-exposed mice were determined following both i.v. and inhalation routes of administration. Both marijuana and Δ9-THC produced comparable levels of antinociception, hypothermia, and catalepsy regardless of the route of administration, and these effects were blocked by pretreatment with the CB1 antagonist SR141716 [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl]. Importantly, the blood and brain levels of Δ9-THC were similar in mice exhibiting similar pharmacological effects, regardless of the presence of non-Δ9-THC marijuana constituents. The present experiments provide evidence that the acute cannabinoid effects of marijuana smoke exposure on analgesia, hypothermia, and catalepsy in mice result from Δ9-THC content acting at CB1 receptors and that the non-Δ9-THC constituents of marijuana (at concentrations relevant to those typically consumed) influence these effects only minimally, if at all.


  • Open Access

    Food for thought: endocannabinoid modulation of lipogenesis

    by Aron H. Lichtman, Benjamin F. Cravatt

    An emerging body of evidence implicates peripheral and central endocannabinoid pathways in the regulation of feeding behavior and body weight. A report in this issue of the JCI demonstrates the presence of a common endocannabinoid-regulated molecular pathway for peripheral lipogenic and central appetitive regulation. This pathway involves the activation of the transcription factor SREBP-1c and its associated enzymes, acetyl-CoA carboxylase-1 and fatty acid synthase, in the liver and hypothalamus. Activation of cannabinoid receptor 1 (CB1) in liver plays a key role in increased serum lipid production, fatty liver, and possibly diet-induced obesity. Conversely, stimulation of these receptors in the hypothalamus may lead to an increase in food consumption. Thus, targeting both of these pathways with CB1 antagonists could promote sustained weight loss and favorable serum lipid profiles in obese patients.


  • Cannabinoid Tolerance and Dependence

    by A. H. Lichtman, B. R. Martin

    The use of marijuana for recreational and medicinal purposes has resulted in a large prevalence of chronic marijuana users. Consequences of chronic cannabinoid administration include profound behavioral tolerance and withdrawal symptoms upon drug cessation. A marijuana withdrawal syndrome is only recently gaining acceptance as being clinically significant. Similarly, laboratory animals exhibit both tolerance and dependence following chronic administration of cannabinoids. These animal models are being used to evaluate the high degree of plasticity that occurs at the molecular level in various brain regions following chronic cannabinoid exposure. In this review, we describe recent advances that have increased our understanding of the impact of chronic cannabinoid administration on cannabinoid receptors and their signal transduction pathways. Additionally, we discuss several potential pharmacotherapies that have been examined to treat marijuana dependence.


  • Disruption of CB1 receptor signaling impairs extinction of spatial memory in mice

    by S. A. Varvel, E. A. Anum, A. H. Lichtman

    Rationale A growing body of in vitro and in vivo evidence indicates that a central endocannabinoid system, consisting of CB1 receptors and endogenous cannabinoids, modulates specific aspects of mnemonic processes. Previous research has demonstrated that either permanent or drug-induced disruption of CB1 receptor signaling interferes with the extinction of a conditioned fear response. Objectives In the present study, we evaluated whether the endocannabinoid system also plays a role in extinguishing learned escape behavior in a Morris water maze task. Methods CB1 (−/−) mice and mice repeatedly treated with 3 mg/kg of the CB1 receptor antagonist SR 141716 (Rimonabant) were trained to locate a hidden platform in the Morris water maze. Following acquisition, the platform was removed and subjects were assigned to either a massed (i.e., five consecutive sessions consisting of four 2-min trials/session) or a spaced (a single, 1-min trial every 2–4 weeks) extinction protocol. Results Strikingly, both 3 mg/kg SR 141716-treated mice and CB1 (−/−) mice continued to return to the target location across all five trials in the spaced extinction procedure, while the control mice underwent extinction by the third or fourth trial. In contrast, both the 3-mg/kg SR 141716-treated and CB1 (−/−) mice exhibited extinction in the massed extinction trial procedure. Conclusions These findings indicate that disruption of CB1 receptor signaling impairs extinction processes in the Morris water maze, thus lending further support to the hypothesis that the endocannabinoid system plays an integral role in the suppression of non-reinforced learned behaviors.


  • ?9-THC-induced cognitive deficits in mice are reversed by the GABAA antagonist bicuculline

    by S. A. Varvel, E. Anum, F. Niyuhire, L. E. Wise, A. H. Lichtman

    Rationale The results of recent in vitro studies have underscored the important role that activation of CB1 receptors has on GABAergic activity in brain areas associated with memory. Objectives The primary purpose of this study was to test the hypothesis that the memory disruptive effects of Δ9-tetrahydrocannabinol (Δ9-THC) in vivo are mediated through GABAergic systems. Conversely, we also evaluated whether blocking CB1 receptor signaling would alter memory deficits elicited by GABA agonists. Methods The GABAA antagonist bicuculline and GABAB antagonist CGP 36742 were evaluated for their ability to ameliorate Δ9-THC-induced deficits in a mouse working memory Morris water maze task. Mice were also assessed in a T-maze task, as well as non-cognitive behavioral assays. Additionally, the effects of GABAA and GABAB agonists were assessed in either CB1 (−/−) mice or wild type mice treated with the CB1 antagonist SR 141716. Results Memory deficits resulting from 10 mg/kg Δ9-THC in the Morris water maze were completely reversed by bicuculline, though unaffected by CGP 36742. Bicuculline also blocked the disruptive effects of Δ9-THC in the T-maze, but failed to alter non-mnemonic effects of Δ9-THC. Although CB1 (−/−) mice exhibited supersensitivity to muscimol-induced water maze deficits compared with wild type control mice, muscimol elicited virtually identical effects in SR 141716-treated and vehicle-treated wild type mice. Conclusions This is the first demonstration of which we are aware showing that GABAA receptors may play a necessary role in Δ9-THC-induced memory impairment in whole animals.


  • Stout Guards of the Central Nervous System

    by R. Mechoulam, A. H. Lichtman

    Endocannabinoids have paradoxical effects on the mammalian nervous system: Sometimes they block neuronal excitability and other times they augment it. In their Perspective, Mechoulam and Lichtman discuss new work (Marsicano et al.) showing that activation of the cannabinoid receptor CB1 by the endocannabinoid anandamide protects against excitotoxic damage in a mouse model of kainic acid-induced epilepsy.


  • The pharmacological activity of inhalation exposure to marijuana smoke in mice

    by Aron H. Lichtman, Justin L. Poklis, Alphonse Poklis, David M. Wilson, Billy R. Martin